Literature DB >> 33683148

Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.

Alexander J Bailey1, Soo-Yon Rhee1, Robert W Shafer1.   

Abstract

There has been no systematic review of the prevalence of transmitted integrase strand transfer inhibitor (INSTI) resistance. We systematically searched the English-language PubMed database and GenBank to identify studies published since 2010 reporting 50 or more INSTI-naive HIV-1-infected adults undergoing integrase genotyping. We extracted data related to country, sample year, specimen type, sequencing method, and subtype. For studies with sequences in GenBank, we determined the prevalence of three categories of INSTI-associated resistance mutations: (1) nonpolymorphic INSTI-selected drug resistance mutations (DRMs) that we refer to as surveillance DRMs; (2) rarely selected nonpolymorphic INSTI-associated DRMs; and (3) common polymorphic accessory INSTI-selected DRMs. A total of 103 studies met inclusion criteria including 75 studies in GenBank containing integrase sequences from 16,481 INSTI-naive persons. The median sample year was 2013 (interquartile range: 2008-2014). The prevalence of INSTI surveillance DRMs, rarely selected DRMs, and common polymorphic accessory INSTI-selected DRMs were 0.5%, 0.8%, and 6.2%, respectively. There was no association between the presence of nonpolymorphic surveillance DRM and region, sample year, or subtype. Two surveillance DRMs, E138K and R263K occurred in 0.15% and 0.10% of naive sequences, respectively. Several lines of evidence suggested that the 0.5% prevalence of surveillance DRMs partly reflects the cumulative natural occurrence of these mutations in the absence of selective drug pressure. There was an unexplained temporal increase in the proportion of sequences with polymorphic accessory mutations. The prevalence of INSTI-associated surveillance DRMs is low even in regions where INSTIs have been a major component of antiretroviral therapy for several years. The presence of INSTI-associated surveillance DRMs in INSTI-naive persons likely results from actual cases of transmitted INSTI resistance and from a low background level reflecting the cumulative rare natural occurrence of several nonpolymorphic mutations.

Entities:  

Keywords:  HIV-1; antiretroviral therapy; drug resistance; integrase; surveillance

Mesh:

Substances:

Year:  2021        PMID: 33683148      PMCID: PMC8665799          DOI: 10.1089/AID.2020.0261

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  20 in total

1.  Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.

Authors:  Nicolas Margot; Stephanie Cox; Moupali Das; Scott McCallister; Michael D Miller; Christian Callebaut
Journal:  Antivir Ther       Date:  2017-01-11

2.  Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.

Authors:  Alexandra U Scherrer; Wan-Lin Yang; Roger D Kouyos; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Matthias Cavassini; Manuel Battegay; Christoph Hauser; Alexandra Calmy; Patrick Schmid; Enos Bernasconi; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2016-04-29       Impact factor: 5.226

3.  Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Authors:  Philip L Tzou; Soo-Yon Rhee; Diane Descamps; Dana S Clutter; Bradley Hare; Orna Mor; Maxime Grude; Neil Parkin; Michael R Jordan; Silvia Bertagnolio; Jonathan M Schapiro; P Richard Harrigan; Anna Maria Geretti; Anne-Geneviève Marcelin; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

4.  Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?

Authors:  Yiannis Koullias; Paul E Sax; Naomi F Fields; Rochelle P Walensky; Emily P Hyle
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

5.  Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Authors:  Kristen N Andreatta; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

6.  Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.

Authors:  Wooyong Jeong; In Young Jung; Heun Choi; Jung Ho Kim; Hye Seong; Jin Young Ahn; Su Jin Jeong; Nam Su Ku; June Myung Kim; Jun Yong Choi
Journal:  AIDS Res Hum Retroviruses       Date:  2018-10-23       Impact factor: 2.205

7.  Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.

Authors:  Sui-Yuan Chang; Pi-Han Lin; Chien-Lin Cheng; Mao-Yuan Chen; Hsin-Yun Sun; Szu-Min Hsieh; Wang-Huei Sheng; Yi-Ching Su; Li-Hsin Su; Shu-Fang Chang; Wen-Chun Liu; Chien-Ching Hung; Shan-Chwen Chang
Journal:  Sci Rep       Date:  2016-10-25       Impact factor: 4.379

8.  Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Huldrych F Günthard; Vincent Calvez; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2019-01-07       Impact factor: 9.079

9.  Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.

Authors:  Neil T Parkin; Santiago Avila-Rios; David F Bibby; Chanson J Brumme; Susan H Eshleman; P Richard Harrigan; Mark Howison; Gillian Hunt; Hezhao Ji; Rami Kantor; Johanna Ledwaba; Emma R Lee; Margarita Matías-Florentino; Jean L Mbisa; Marc Noguera-Julian; Roger Paredes; Vanessa Rivera-Amill; Ronald Swanstrom; Daniel J Zaccaro; Yinfeng Zhang; Shuntai Zhou; Cheryl Jennings
Journal:  Viruses       Date:  2020-06-27       Impact factor: 5.048

10.  Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK.

Authors:  Jean L Mbisa; Juan Ledesma; Peter Kirwan; David F Bibby; Carmen Manso; Andrew Skingsley; Gary Murphy; Alison Brown; David T Dunn; Valerie Delpech; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

View more
  2 in total

1.  Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.

Authors:  Dawit Assefa Arimide; Zsófia Ilona Szojka; Kidist Zealiyas; Atsbeha Gebreegziabxier; Fekadu Adugna; Sviataslau Sasinovich; Per Björkman; Patrik Medstrand
Journal:  Viruses       Date:  2022-03-30       Impact factor: 5.818

2.  Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA.

Authors:  Vlad Novitsky; Jon Steingrimsson; Fizza S Gillani; Mark Howison; Su Aung; Matthew Solomon; Cindy Y Won; Amy Brotherton; Rajeev Shah; Casey Dunn; John Fulton; Thomas Bertrand; Anna Civitarese; Katharine Howe; Theodore Marak; Philip Chan; Utpala Bandy; Nicole Alexander-Scott; Joseph Hogan; Rami Kantor
Journal:  Open Forum Infect Dis       Date:  2021-12-07       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.